Scott Berkowitz

Professor of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Scott Berkowitz is a Professor of Medicine at CPC Clinical Research and CU Anschutz in the United States. His research primarily focuses on peripheral artery disease, examining the efficacy of antithrombotic therapies and sex-based differences in treatment outcomes. Recent articles include studies on Rivaroxaban and its implications for patients undergoing revascularization and broader analyses of clinical factors in cardiovascular health.

Articles (19)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Danilo Toni

Sapienza University

ITALY

View details

Robert Welsh

University of Alberta

CANADA

View details

Gilles R. Dagenais

Professeur émérite

Laval University

CANADA

View details

Kelley Branch

Professor

University of Washington

UNITED STATES

View details

Plinio Cirillo

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Scott Berkowitz

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions

Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials

Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone

Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease

Microbleeds and the Effect of Anticoagulation in Patients with Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease

Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial

Risk stratification of cardiovascular complications using CHA<inf>2</inf>DS<inf>2</inf>-VASc and CHADS<inf>2</inf> scores in chronic atherosclerotic cardiovascular disease

Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial

Rivaroxaban and Aspirin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial

Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

EFFICACY AND SAFETY OF LOW-DOSE RIVAROXABAN IN SYMPTOMATIC PAD PATIENTS UNDERGOING REVASCULARIZATION CURRENTLY SMOKING: INSIGHTS FROM VOYAGER PAD

EFFICACY AND SAFETY OF RIVAROXABAN IN ELDERLY PATIENTS WITH SYMPTOMATIC PAD UNDERGOING REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation

Collaborators (5)

Danilo Toni

Robert Welsh

Gilles R. Dagenais

Kelley Branch

Plinio Cirillo

Make your next move.